In this study, we showed for the first time that a new drug, IP-DNQ, exerts high cytotoxicity towards NSCLC and breast cancer cells in an NQO1-dependent manner and that it elicited efficacious antitumor responses against mice bearing A549 orthotopic lung tumors. This evidence concerns the gene NQO1 and breast cancer.